Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

BEAt-DKD

Financiado

Cerrado

Biomarker Enterprise to Attack DKD Sofia ref. 115974

Diabetic kidney disease (DKD) is the leading cause of end stage renal disease (ESRD), and its global incidence and prevalence have reached epidemic dimensions in recent years. Unfortunately, there are no effective means to prevent... ver más

31/08/2023

LUNDS UNIVERSITET

31M€

Presupuesto del proyecto: 31M€

Líder del proyecto

LUNDS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 37 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-08-31

IMI2-2015-05-02: Diabetic Kidney Disease Biomarkers...

I+D

Cerrada hace 9 años

0% 49% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

37 Participantes

LUNDS UNIVERSITET

2.51M€ | Lider

UNIVERSITY OF BRISTOL

583.88K€ | Participante

BAYER AKTIENGESELLSCHAFT

340.00K€ | Participante

UOXF

5.08K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

TargetCKD Identification of novel diagnostic, predictive and therapeut... 2M€ Cerrado

PROCEED Proteomics for Chronic Kidney Disease Therapy 171K€ Cerrado

DECODE-DKD Decoding diabetic kidney disease 2M€ Cerrado

IMODE-CKD Clinical and system omics for the identification of the MOl... 3M€ Cerrado

SYSKID Systems biology towards novel chronic kidney disease diagnos... 16M€ Cerrado

AI CARE Integrated AI-Driven Systems For Kidney Transplant Precision... 2M€ Cerrado

Duración del proyecto: 80 meses Fecha Inicio: 2016-12-20
Fecha Fin: 2023-08-31

Líder del proyecto

LUNDS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 31M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Diabetic kidney disease (DKD) is the leading cause of end stage renal disease (ESRD), and its global incidence and prevalence have reached epidemic dimensions in recent years. Unfortunately, there are no effective means to prevent or cure DKD, the few existing treatments have limited effect and very few alternative therapies have emerged in the past years. Lack of new predictive and prognostic biomarkers for a more accurate patient stratification, limited access to kidney tissue from patients at various stages of DKD as well as novel model systems to better understand the pathogenesis of the disease, are likely reasons for the stagnating development of new treatments. The BEAt-DKD consortium combines outstanding basic and translational researchers in nephropathy, diabetes, kidney model systems, imaging techniques and systems biology, and includes leaders of diabetes and kidney disease-relevant IMI1, FP7 and US consortia, like SUMMIT, KIDNEYCONNECT, Syskid, CPROBE and C-Path, in an unprecedented search for new and better biomarkers for DKD, through a better understanding of the disease. Jointly, the partners have access to vast and very relevant clinical cohorts and trials, state-of-the-art analysis and imaging techniques, novel model systems and the long-standing experience and networks to make this collaboration a success. By involving regulatory agencies throughout the project, BEAt-DKD aims at making the introduction and acceptance of new tools as efficient as possible. The overall goals of BEAt-DKD are (1) to provide a holistic systems medicine view of the pathogenesis of DKD with the aim to identify targetable mechanisms and pathways underlying initiation and progression of DKD, applying a novel sub-classification of diabetes, and (2) to identify and validate biomarkers of disease progression and treatment responses representing first steps towards precision medicine in the management of DKD.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores